Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Camizestrant→

Camizestrant Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2222844-89-3
Molecular formula
C24H28F4N6
Molecular weight
476.5 g/mol
Drug class
Selective estrogen receptor degrader (SERD)oral endocrine antineoplastic
Mechanism of action
Binds to the oestrogen receptor and promotes receptor degradation, reducing oestrogen-receptor signalling in hormone-receptor-positive breast cancer cells.
Indications / reported uses
  • In combination with abemaciclib, palbociclib or ribociclib for adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer after detection of an ESR1 mutation during first-line aromatase-inhibitor plus CDK4/6-inhibitor therapy, without disease progression; the authorisation is under accelerated/conditional approval frameworks and requires current product-label confirmation
View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Camizestrant Environmental Risk Assessment (ERA) (the Camizestrant ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.